Cervical cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age =18 years old; 2) female; 3) Cervical cancer diagnosed by pathology (including histology or cytology); patients with clinical stage of cervical cancer (FIGO stage) IB3, II-IVA; 4) ECOG PS: 0-2 points; 5) Expected survival period = 6 months; 6) Subjects voluntarily joined the study, signed a written informed consent before any trial-related procedures were implemented, and had good compliance and cooperated with follow-up; 7) All organ functions are basically normal (laboratory test results within one week before enrollment without continuous supportive treatment): white blood cells>3.5 × 10 ^ 9/L, neutrophils>1.5 × 10 ^ 9/L, platelets>100 × 10 ^ 9/L, hemoglobin>9.0g/dl; AST (SGOT), ALT (SGPT)<2.5 × ULN;
Exclusion criteria
Exclusion criteria: 1) Patients without pathological diagnosis; 2) Currently participating in interventional clinical research treatment, or receiving treatment with other investigational drugs or investigational devices within 8 weeks before radiotherapy; 3) Class III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmias; 4) Known mental illness or substance abuse that may affect compliance with trial requirements; 5) Known history of human immunodeficiency virus (HIV) infection (ie HIV 1/2 antibody positive), active pulmonary tuberculosis; 6) Patients undergoing total cervical resection; 7) Suffering from other tumor diseases at the same time. 8) Investigators deem unsuitable for inclusion.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS;Overall Survival, OS; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR; | — |
Countries
China
Contacts
Capital Medical University Cancer Canter, Beijing Shijitan Hospital